improve it or discuss these issues on the talk page . learn how and when to remove these template messages a major contributor to this article appears to have a close connection with its subject . it may require cleanup to comply with wikipedia s content policies particularly neutral point of view . please discuss further on the talk page . july 2011 learn how and when to remove this template message this article needs additional citations for verification . please help improve this article by adding citations to reliable sources . unsourced material may be challenged and removed . december 2011 learn how and when to remove this template message this article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral . please help improve it by replacing them with more appropriate citations to reliable independent third party sources . december 2011 learn how and when to remove this template message learn how and when to remove this template message neurosearch a s is a danish biotechnology company specializing in pharmaceuticals for treating diseases and disorders affecting the central nervous system cns . history edit neurosearch was founded in denmark in april 1989 as one of the first companies in the medicon valley area around copenhagen and malm with 25 employees and 4 000 000 in private financing . its danish founders included femoxetine and paroxetine inventor j rgen buus lassen and asger aamund da . in 1996 neurosearch was listed on nasdaq omx copenhagen a s under the ticker symbol neur.co . in 2006 three drug candidates from a novel class of compounds the company refers to as dopaminergic stabilizers were added to the development pipeline through the acquisition of carlsson research ab a privately owned swedish company . in 2010 neurosearch reported the results of mermaihd multinational european multicentre acr16 study in huntington s disease the first study in the huntexil phase 3 programme . this study examined the effects of huntexil in almost 440 patients with huntington s disease but despite some suggestion of improved motor function the drug did not produce improvement on the study s primary endpoint . 1 the us food and drug administration and european medicines agency have instructed neurosearch that a successful phase 3 trial that meets its primary motor endpoint will be needed if the drug is to be approved for patient use . 2 in 2008 results demonstrating significant weight loss for tesofensine compared with placebo were published in the lancet . the investigators concluded that tesofensine could produce at least twice the weight loss of currently approved anti obesity drugs and should be evaluated in phase 3 trials . 3 neutrality is disputed in 2012 the company was no longer able to attract funding for continuing its r & d activities . the company sold its rights to its lead product candidate huntexil for the treatment of patients with huntington s disease to teva pharmaceutical industries . the clinical development of the remaining pipeline projects was stopped and the company is still trying to sell the remaining assets . in 2014 neurosearch transferred the rights to tesofensine to saniona . 4 references edit de yebenes justo garcia ; landwehrmeyer bernhard squitieri ferdinando reilmann ralf rosser anne barker roger a saft carsten magnet markus k sword alastair rembratt sa tedroff joakim 1 december 2011 . pridopidine for the treatment of motor function in patients with huntington s disease mermaihd a phase 3 randomised double blind placebo controlled trial . the lancet neurology . 10 12 1049 1057 . doi 10.1016 s1474 4422 11 70233 2 . pmid 22071279 . cite uses deprecated parameter coauthors help huntexil update ema asks for further trial . hdbuzz . retrieved 11 december 2011 . astrup a madsbad s breum l jensen tj kroustrup jp larsen tm 2008 . effect of tesofensine on bodyweight loss body composition and quality of life in obese patients a randomised double blind placebo controlled trial . lancet . 372 9653 1906 13 . doi 10.1016 s0140 6736 08 61525 1 . pmid 18950853 . neurosearch a s signs agreement to transfer phase i ii projects ns2359 and ns2330 tesofensine . neurosearch company announcement . retrieved 30 october 2014 . external links edit official website retrieved from https en.wikipedia.org w index.php title neurosearch & oldid 723623141 categories biotechnology companies of denmarklife science companies based in copenhagencompanies established in 1989hidden categories pages containing cite templates with deprecated parameterswikipedia articles with possible conflicts of interest from july 2011articles needing additional references from december 2011all articles needing additional referencesarticles lacking reliable references from december 2011all articles lacking reliable referencesall articles with minor pov problemsarticles with minor pov problems from december 2011 navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages dansksvenska edit links this page was last modified on 4 june 2016 at 04 18 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view